Welcome to our dedicated page for Mawson Infrastructure Group news (Ticker: $MIGI), a resource for investors and traders seeking the latest updates and insights on Mawson Infrastructure Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mawson Infrastructure Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mawson Infrastructure Group's position in the market.
Rhea-AI Summary
Mawson Infrastructure Group Inc. (NASDAQ:MIGI) has signed a new co-location agreement with Faith Technologies Incorporated for approximately 1,176 miners or 4 MW at Mawson’s Midland, Pennsylvania facilities. This agreement is the third co-location customer agreement executed by Mawson since the start of Q4, 2023, developing a multi-customer base for Mawson’s co-location business and providing additional growth opportunities. The company anticipates its Midland facilities operating at a total capacity of 100 MW with the combined potential for self-mining and co-location fleets at its Midland facilities comprising approximately 32,930 miners and 3.8 EH/s. Mawson’s facilities are expected to have a capacity of 100 MW with self-mining and the total co-location platforms combined.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
-
Rhea-AI Summary
In December, MIGI's co-location and self-mining business revenue saw substantial month-over-month increases of 34% and 27% respectively. Additionally, the company completed its second co-location customer deployment of approximately 6 MW and 1,764 miners, contributing to the growth in total revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
-
Rhea-AI Summary
Mawson Infrastructure Group Inc. (NASDAQ:MIGI) reported a 47% increase in total revenue for November 2023. The company completed a co-location customer deployment of approximately 50 MW and 15,876 miners, and signed an additional co-location customer for approximately 6 MW and 1764 miners. CEO Rahul Mewawalla expressed excitement about the company's growth prospects in the co-location business for December 2023 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.03%
Tags
Rhea-AI Summary
Mawson Infrastructure Group (MIG) signs new customer agreement for 1,764 miners with provision for expansion, expecting full deployment by year-end, with a total capacity of 35,624 miners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.71%
Tags
-
Rhea-AI Summary
Mawson Infrastructure Group Inc. (NASDAQ:MIGI) reported a total monthly revenue equivalent of 110 BTC1 in October 2023. The company also signed a new co-location customer agreement for around 50 MW and 15,876 miners. Mawson is focused on optimizing revenue and margin across its three primary businesses – Bitcoin self-mining, co-location services, and energy management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Mawson Infrastructure Group Inc. (NASDAQ: MIGI) announced a 41% increase in self-mined Bitcoin revenue and a 35% increase in Bitcoin mined to $6.9 million and 246 BTC, respectively, for Q3 FY 2023. Total Quarterly Revenue increased to $11.3 million, while SG&A Expenses decreased 42% Q/Q. The company also announced a new co-location customer agreement and upcoming conferences and events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
Rhea-AI Summary
Mawson Infrastructure Group Inc. signs co-location agreement with Consensus Technology Group LLC for about 15,876 Bitmain Antminer S19 XP miners and approximately 50 MW of power.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Mawson Infrastructure Group has signed a customer co-location agreement with Consensus Technology Group for the provision of co-location services for approximately 15,876 Bitmain Antminer S19 XP miners or approximately 50 MW at Mawson's Midland, Pennsylvania facilities. The agreement is for 12 months with the possibility of extension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
-
Rhea-AI Summary
Mawson Infrastructure Group Inc. announces unaudited business and operational update for September 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
Rhea-AI Summary
Mawson Infrastructure Group appoints former U.S. Congressman Ryan Costello as a Member of the Board of Directors, bringing valuable knowledge in digital assets, technology, and energy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
Mawson Infrastructure Group Inc.
Nasdaq:MIGI
MIGI Rankings
MIGI Stock Data
22.07M
14.11M
15.23%
7.24%
4.79%
Data Processing, Hosting, and Related Services
Information
United States of America
SHARON
About MIGI
wize pharma, inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including des. wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as lo2a, a drug developed for the treatment of des, and other ophthalmological illnesses, including cch and sjögren's syndrome (sjögren's). lo2a is currently registered and marketed by its inventor in germany and switzerland for the treatment of des, in hungary for the treatment of des, cch and sjögren's and in the netherlands for the treatment of des and sjögren's. wize's strategy involves engaging local or multinational distributors to handle the distribution of lo2a. wize has finished a phase ii trial of lo2a for patients with cch and is currently conducting a phase iv study for lo2a for des in patients with sjögren's.